The limited options for specific therapies for TNBC combined with the development of resistance to therapies for ER+, PR+ and HER2 + breast cancer highlight that therapeutic challenges still are considerable [1], and that a deeper understanding of the molecular mechanisms driving development and progression of breast cancer is warranted. This evidence concerns the gene ESR1 and breast carcinoma.